Palatin Technologies (PTN) investor relations material

Executive summary

• Advanced melanocortin receptor (MCR) agonist pipeline, focusing on rare neuroendocrine and genetic obesity disorders, with lead MC4R programs targeting hypothalamic obesity and Prader-Willi syndrome and additional MC1R assets for ocular, gastroenterology, and renal indications.

• Strengthened financial position through an $18.2 million public offering, regaining NYSE American listing compliance, and significant equity financing and warrant exercises totaling $18.35 million in the six months.

• Entered a major research collaboration and license agreement with Boehringer Ingelheim for retinal disease therapeutics, generating upfront and milestone revenue.

• Sublicensed PL9643 for dry eye disease, securing $3.8 million in upfront non-cash debt cancellation and eligibility for future milestones and royalties.

Financial highlights

• Collaboration and license revenue rose to $8.96 million for the six months ended December 31, 2025, mainly from the Boehringer Ingelheim agreement; Q2 FY26 revenue was $116,036, up from $0 year-over-year.

• Operating expenses increased to $7.4 million for the quarter, driven by higher R&D and compensation costs.

• Net loss for Q2 FY26 was $7.3 million ($2.86/share), compared to $2.4 million ($5.92/share) in the prior year; net loss for the six months was $2.59 million.

• Cash and cash equivalents stood at $14.5 million as of December 31, 2025, with current liabilities of $6.33 million.

• Cash runway expected to extend beyond March 31, 2027.

Outlook and guidance

• IND submission and Phase 1 trial for oral MC4R agonist PL7737 planned for H1 2026; next-generation peptide MC4R agonist IND submission targeted for H2 2026.

• Multiple clinical trials for rare MC4R pathway diseases are planned for calendar year 2026.

• Phase II/III studies in hypothalamic obesity and Prader-Willi syndrome to begin after mid-2027.

• Sufficient cash on hand to fund phase 1 studies for both oral and peptide programs.

• Additional funding will be required to complete clinical trials and regulatory submissions.